胸苷激酶1和Ki67在乳腺癌中的表达及其对预后的价值

doi:10.3760/cma.j.issn.1673-422X.2013.11.020

摘要/Abstract

摘要： 目的探讨胸苷激酶1（TK1）、Ki67单独表达及联合表达对乳腺癌复发转移的影响。方法选取广州医学院第二附属医院乳腺外科2005年3月至2007年6月间手术切除的乳腺癌患者组织标本65例，均经病理证实。分为A、B两组，A组37例，为乳腺癌在5年内出现复发或转移者，B组28例，为无瘤生存超过5年者。分别测量A、B两组TK1及Ki67表达情况并描述生存曲线。结果TK1 A组阳性率为91.8％，B组阳性率67.8％（χ2=6.116, P=0.013），Ki67 A组阳性率为78.4％，B组阳性率42.9％（χ2=8.635, P=0.003）。A、B两组TK1和Ki67均呈阳性表达的比率分别为67.6％和39.3％（χ2=5.159, P=0.023）。经KaplanMeier法生存曲线证实，与TK1和Ki67单独阳性表达者相比，联合阳性表达者的无瘤生存率显著降低，差异有统计学意义（χ2=6.137,P=0.046）。结论TK1、Ki67均阳性表达是乳腺癌复发转移的高危因素，其预后较两者单独阳性表达者更差。

关键词: 乳腺肿瘤, 胸苷激酶, Ki67

Abstract: ObjectiveTo investigate the effects of the expressions of thymidine kinase 1 (TK1) and Ki67 alone or their combination on the recurrence and metastasis of breast cancer. MethodsSixtyfive samples were selected from the Second Affiliated Hospital of Guangzhou Medical University from March 2005 to June 2007, which were resected by surgical operation and confirmed as breast carcinoma by pathology. They were individed into two groups including 37 cases with recurrence or metastasis in 5 years (group A), 28 cases without recurrence or metastasis in 5 years (group B). The expressions of TK1 and Ki67 in the two groups were detected by immunohistochemical staining assay. Then, KaplanMeier assay was used to describe survival curve. ResultsThe positive expression rate of TK1 in group A was 91.8％, which was dramatically higher than that in group B 67.8％ (χ2=6.116, P=0.013). The positive expression rates of Ki67 in group A and B were 78.4％ and 42.9％ (χ2=8.635, P=0.003). The positive expression rates of TK1 combined with Ki67 in group A and B were 67.6％ and 39.3％ (χ2=5.159, P=0.023). Moreover, disease free survival of patients with positive expression of TK1 combined with Ki67 decreased significantly, compared with patients with positive expression of TK1 or Ki67 alone (χ2=6.137, P=0.046). ConclusionPositive expression of TK1 combined with Ki67 is the high risk factor of the reccurence or metastasis of breast carcinoma, and indicates poorer prognosis compared with positive expression alone.

Key words: Breast neoplasms, Thymidine kinase, Ki67

夏婷, 章乐虹, 曹腾飞, 等. 胸苷激酶1和Ki67在乳腺癌中的表达及其对预后的价值[J]. 国际肿瘤学杂志, 2013, 40(11): 867-870.

Xia-Ting, ZHANG Le-Hong, CAO Teng-Fei, et al. Expression and prognostic significance of TK1 and Ki67 in breast cancer[J]. Journal of International Oncology, 2013, 40(11): 867-870.

参考文献

［1］ Johnson LF, Rao LG, Muench AJ. Regulation of thymidine kinase enzyme level in serumstimulated mouse 3T6 fibroblasts. Exp Cell Res, 1982,138(1):79-85. ［2］ Wu BJ, Li WP, Qian C, et al. Increased serum level of thymidine kinase 1 correlates with metastatic site in patients with malignant melanoma. Tumour Biol, 2013,34(2):643-648. ［3］ Mao Y, Wu J, Skog S, et al. Expression of cell proliferating genes in patients with nonsmall cell lung cancer by immunohistochemistry and cDNA profiling. Oncol Rep, 2005, 13(5):837-846. ［4］ Broet P, Romain S, Daver A, et al. Thymidine kinase as a proliferative marker: clinical relevance in 1,692 primary breast cancer patients. J Clin Oncol, 2001,19(11):2778-2787. ［5］李树玲. 乳腺癌防治研究回顾与展望. 国外医学肿瘤学分册, 2000, 27(1): 14-17．［6］ He Q, Fornander T, Johansson H, et al. Thymidine kinase 1 in serum predicts increased risk of distant or loco-regional recurrence following surgery in patients with early breast cancer. Anticancer Res, 2006,26(6C):4753-4759. ［7］ Zhang J, Jia Q, Zou S, et al. Thymidine kinase 1: a proliferation marker for determining prognosis and monitoring the surgical outcome of primary bladder carcinoma patients. Oncol Rep, 2006,15(2):455-461. ［8］ Agarwal HK, McElroy CA, Sjuvarsson E, et al. Synthesis of N3-substituted carboranyl thymidine bioconjugates and their evaluation as substrates of recombinant human thymidine kinase 1. Eur J Med Chem, 2013, 60:456-468. ［9］ Huang ZH, Tian XS, Li R, et al. Elevated thymidine kinase 1 in serum following neoadjuvant chemotherapy predicts poor outcome for patients with locally advanced breast cancer. Exp Ther Med, 2012,3(2):331-335. ［10］ Liu Y, Ling Y, Qi Q, et al. Changes in serum thymidine kinase 1 levels during chemotherapy correlate with objective response in patients with advanced gastric cancer. Exp Ther Med, 2011, 2(6):1177-1181. ［11］ Huang ZH, Tian XS, Li R, et al. Elevated thymidine kinase 1 in serum following neoadjuvant chemotherapy predicts poor outcome for patients with locally advanced breast cancer. Exp Ther Med, 2012,3(2):331-335. ［12］ Kang NH, Hwang KA, Yi BR, et al. Human amniotic fluid-derived stem cells expressing cytosine deaminase and thymidine kinase inhibits the growth of breast cancer cells in cellular and xenograft mouse models. Cancer Gene Ther, 2012,19(6): 412-419. ［13］陈飞宇, 唐利立, 黄隽. S-TK1在乳腺癌患者新辅助化疗前后检测的意义. 中国肿瘤临床, 2009,36(13):732735. ［14］ Mohammed ZM, McMillan DC, Elsberger B, et al. Comparison of visual and automated assessment of Ki-67 proliferative activity and their impact on outcome in primary operable invasive ductal breast cancer. Br J Cancer, 2012, 106(2):383- 388. ［15］ Veronese SM, Gambacorta M, Gottardi O, et al. Proliferation index as a prognostic marker in breast cancer. Cancer, 1993, 71(12): 3926-3931.

[1]	王盈, 刘楠, 郭兵. 抗体药物偶联物在转移性乳腺癌治疗中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 364-369.
[2]	萨蔷, 徐航程, 王佳玉. 乳腺癌免疫治疗研究进展[J]. 国际肿瘤学杂志, 2024, 51(4): 227-234.
[3]	杨智, 陆以乔, 顾花艳, 丁佳玲, 郭贵龙. 肿瘤微环境介导乳腺癌靶向治疗耐药的研究进展[J]. 国际肿瘤学杂志, 2024, 51(4): 235-238.
[4]	陈波光, 王苏贵, 张永杰. 血清胆碱酯酶与炎症标志物在ⅠA~ⅢA期乳腺癌预后中的作用[J]. 国际肿瘤学杂志, 2024, 51(2): 73-82.
[5]	顾花艳, 朱腾, 郭贵龙. 乳房微生物群与乳腺癌：现状与未来[J]. 国际肿瘤学杂志, 2024, 51(1): 55-58.
[6]	王景, 许文婷. 中性粒细胞与淋巴细胞比值、癌胚抗原联合凝血指标对直径≤1.0 cm的良恶性乳腺结节鉴别诊断价值研究[J]. 国际肿瘤学杂志, 2023, 50(9): 520-526.
[7]	冯诚天, 黄芙蓉, 曹世玉, 王健宇, 南丁阿比雅思, 姜永冬, 朱娟英. HER2阳性乳腺癌患者HER2表达水平与影像学特征的关系[J]. 国际肿瘤学杂志, 2023, 50(9): 527-531.
[8]	冯东旭, 吴炜, 高平发, 王军, 施丽娟, 陈大伟, 李文兵, 张美峰. miR-451通过调控Rho/ROCK1信号通路对乳腺癌细胞糖酵解及凋亡的影响[J]. 国际肿瘤学杂志, 2023, 50(8): 449-456.
[9]	王文德, 曾德. 乳腺癌内分泌治疗耐药的机制研究进展[J]. 国际肿瘤学杂志, 2023, 50(6): 352-356.
[10]	李青珊, 谢鑫, 张楠, 刘帅. 放疗联合系统治疗在乳腺癌中的应用进展[J]. 国际肿瘤学杂志, 2023, 50(6): 362-367.
[11]	朱军, 黄美金, 李媛, 刘泽刚, 荀欣, 陈宏. HER2低表达乳腺癌的靶向治疗研究进展[J]. 国际肿瘤学杂志, 2023, 50(4): 236-240.
[12]	周婷, 徐少华, 梅林. 贝伐珠单抗联合卡培他滨治疗晚期乳腺癌的有效性及安全性[J]. 国际肿瘤学杂志, 2023, 50(3): 144-149.
[13]	黎立喜, 张娣, 罗扬, 马飞. PARP抑制剂在乳腺癌中的临床应用[J]. 国际肿瘤学杂志, 2023, 50(2): 91-96.
[14]	陈群响, 张晓钰, 张妍, 张凯翔, 李捷, 陈曦. 伊尼妥单抗联合长春瑞滨治疗HER2阳性转移性乳腺癌1例[J]. 国际肿瘤学杂志, 2023, 50(12): 763-765.
[15]	耿睿, 马俊强, 郭强, 牛钊峰. 老年乳腺癌患者的综合治疗方式选择倾向及其影响因素[J]. 国际肿瘤学杂志, 2023, 50(11): 650-654.